--- title: "Altimmune (ALT) news: offering" url: "https://aibio.space/companies/altimmune/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "ALT offering news: Altimmune launches stock and warrant offering, later prices it at $3.00. Altimmune, Inc. (NASDAQ: ALT), United States." --- ALT Altimmune, Inc. NASDAQ · United States # Altimmune (ALT) news ALT offering news Debt Financing · 2026-10-29 ## [Altimmune draws $10.0 million third tranche from Hercules loan facility](https://aibio.space/news/altimmune-draws-10-0-million-third-tranche-hercules-loan-facility/) Altimmune drew $10.0 million on October 27, 2026, and the draw extended the interest-only period to June 1, 2028 while adding a minimum cash covenant tied to the loan balance. ## Latest Altimmune news 1. 2026-04-22 Financings [Altimmune launches stock and warrant offering, later prices it at $3.00](https://aibio.space/news/altimmune-launches-stock-warrant-offering-later-prices-3-00/) Altimmune sold 64,250,000 shares at $3.00 with a warrant for each share, against a last reported sale price of $3.47 on April 22, 2026. 2. 2026-04-16 Listings [Altimmune holders approve doubling authorized shares to 400,000,000](https://aibio.space/news/altimmune-holders-approve-doubling-authorized-shares-400-000-000/) Shareholders approved raising authorized common stock from 200,000,000 to 400,000,000 shares, against 130,105,177 shares outstanding at the March 13, 2026 record date. 3. 2026-01-28 Financings [Altimmune agrees to $75 million registered direct offering with one new investor](https://aibio.space/news/altimmune-agrees-75-million-registered-direct-offering-one-new/) Altimmune is selling 12,397,920 shares at $4.40 each, plus pre-funded warrants for 4,647,534 shares, to one investor, with Titan Partners Group LLC as sole placement agent. 4. 2025-11-06 Debt Financing [Altimmune expands Hercules loan facility to $125 million and draws $20 million](https://aibio.space/news/altimmune-expands-hercules-loan-facility-125-million-draws-20-million/) The amendment raises term loan availability from $100.0 million to $125.0 million and extends the interest-only period to 30 months. Altimmune held $210.8 million in cash, cash equivalents and short-term investments at September 30, 2025. 5. 2025-05-13 Debt Financing [Altimmune draws $15.0 million under Hercules loan agreement for up to $100.0 million](https://aibio.space/news/altimmune-draws-15-0-million-under-hercules-loan-agreement-up-100-0/) The term loan has four tranches and matures June 1, 2029. The company reported $150 million in cash, cash equivalents and short-term investments as of March 31, 2025. 6. 2025-02-27 Financings [Altimmune files $400,000,000 shelf with $150,000,000 equity distribution program](https://aibio.space/news/altimmune-files-400-000-000-shelf-150-000-000-equity-distribution/) Altimmune's $400 million shelf would also carry a $150 million share sales program, with Leerink Partners, Piper Sandler and Stifel as sales agents. The filing itself sells no shares. ## Altimmune at a glance - **Ticker**: ALT - **Listing**: NASDAQ - **Country**: United States - **Cash, Jun 30, 2026**: $326.3 million ### Related companies - [BioVie](https://aibio.space/companies/biovie/) NASDAQ: BIVI - [Eloxx Pharmaceuticals](https://aibio.space/companies/eloxx-pharmaceuticals/) NASDAQ: ELOX - [Nevis Brands](https://aibio.space/companies/nevis-brands/) CSE: NEVI - [Design Therapeutics](https://aibio.space/companies/design-therapeutics/) NASDAQ: DSGN - [Life Stem Genetics](https://aibio.space/companies/life-stem-genetics/) OTC: LIFS - [AnaptysBio](https://aibio.space/companies/anaptysbio/) NASDAQ: ANAB - [CLARITAS PHARMACEUTICALS INC.](https://aibio.space/companies/claritas-pharmaceuticals/) OTC: CLAZF - [UMeWorld](https://aibio.space/companies/umeworld/) OTC: UMEW ### Also on NASDAQ - [LENZ Therapeutics](https://aibio.space/companies/lenz-therapeutics/) LENZ - [Virax Biolabs Group](https://aibio.space/companies/virax-biolabs/) VRAX - [LEMAITRE VASCULAR INC](https://aibio.space/companies/lemaitre-vascular/) LMAT - [MediciNova](https://aibio.space/companies/medicinova/) MNOV - [FibroBiologics](https://aibio.space/companies/fibrobiologics/) FBLG - [MYRIAD GENETICS INC](https://aibio.space/companies/myriad-genetics/) MYGN ## What Altimmune does Altimmune, Inc. develops pemvidutide, its lead product candidate, which it is studying in three indications. In MASH, the IMPACT Phase 2b trial reported positive 48-week topline results on December 19, 2025, with statistically significant improvements versus placebo across treatment arms in the anti-fibrosis measures ELF and LSM. The company lists the conduct of a Phase 3 clinical trial for pemvidutide in MASH among its planned activities. For AUD, the RECLAIM Phase 2 trial completed enrollment, the FDA granted Fast Track designation, and topline results are expected in 2026. For ALD, the RESTORE Phase 2 trial began enrolling in July 2025 across 34 sites in the United States. The company has not generated revenue from product sales to date, and its earlier revenue came mainly from government and foundation grants and contracts. Its consolidated accounts include Altimmune UK, Ltd, Spitfire Pharma, LLC and Altimmune AU Pty, Ltd. | Product or program | What it is | Stage | |---|---|---| | pemvidutide | Lead product candidate studied in MASH, AUD and ALD | Phase 2b completed in MASH (IMPACT); Phase 2 in AUD and ALD | | RECLAIM | Phase 2 trial of pemvidutide in AUD | Phase 2; enrollment completed | | RESTORE | Phase 2 trial of pemvidutide in ALD | Phase 2 | Summarised from the company's [10-K filed Mar 6, 2026](https://www.sec.gov/Archives/edgar/data/1326190/000132619026000018/alt-20251231x10k.htm). ## Altimmune annual financials | Line | FY2025 | FY2024 | |---|---|---| | Revenue | [$41,000](https://www.sec.gov/Archives/edgar/data/1326190/000132619026000018/) | [$20,000](https://www.sec.gov/Archives/edgar/data/1326190/000132619026000018/) | | Research and development | [$66.4 million](https://www.sec.gov/Archives/edgar/data/1326190/000132619026000018/) | [$82.2 million](https://www.sec.gov/Archives/edgar/data/1326190/000132619026000018/) | | Net income (loss) | [-$88.1 million](https://www.sec.gov/Archives/edgar/data/1326190/000132619026000018/) | [-$95.1 million](https://www.sec.gov/Archives/edgar/data/1326190/000132619026000018/) | | Cash from operations | [-$67.5 million](https://www.sec.gov/Archives/edgar/data/1326190/000132619026000018/) | [-$79.8 million](https://www.sec.gov/Archives/edgar/data/1326190/000132619026000018/) | | Cash and equivalents | [$43.8 million](https://www.sec.gov/Archives/edgar/data/1326190/000132619026000052/) | [$36.9 million](https://www.sec.gov/Archives/edgar/data/1326190/000132619026000018/) | | Short-term investments | [$229.7 million](https://www.sec.gov/Archives/edgar/data/1326190/000132619026000052/) | [$95.0 million](https://www.sec.gov/Archives/edgar/data/1326190/000132619026000018/) | Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $63.0 million, plus short-term investments of $263.3 million, $326.3 million in all. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about Altimmune Has Altimmune raised money recently? Our latest story on this, dated Apr 22, 2026: "Altimmune launches stock and warrant offering, later prices it at $3.00". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/altimmune-launches-stock-warrant-offering-later-prices-3-00/). What is the ticker symbol of Altimmune? Altimmune, Inc. trades under the ticker ALT on NASDAQ. Where is Altimmune listed? Altimmune, Inc. is listed on NASDAQ. Our directory also records these other listings: BIVA:ALT1; BMV:ALT1; GETTEX:3G0; LS:A2N5Z6; LSX:A2N5Z6. What is the SEC CIK of Altimmune? The SEC Central Index Key (CIK) for Altimmune, Inc. is 1326190. Its filings are on SEC EDGAR. How many shares does Altimmune have outstanding? 194,517,701 shares as of 2026-08-07, per the cover page of its 10-Q filed 2026-08-12. Which country or territory is Altimmune listed under? Our directory records Altimmune, Inc. under United States. What does Altimmune do? Our directory classifies Altimmune, Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline. What is the ISIN of Altimmune? The ISIN recorded for Altimmune, Inc. is US02155H2004. Does aibio.space cover Altimmune? aibio.space lists Altimmune, Inc. among 2,820 public biotech companies and publishes its news here as stories appear. Where is Altimmune incorporated? SEC records list its state or country of incorporation as DE. What does Altimmune develop? Altimmune, Inc. develops pemvidutide, its lead product candidate, which it is studying in three indications. In MASH, the IMPACT Phase 2b trial reported positive 48-week topline results on December 19, 2025, with statistically significant improvements versus placebo across treatment arms in the anti-fibrosis measures ELF and LSM. What is pemvidutide from Altimmune? pemvidutide: Lead product candidate studied in MASH, AUD and ALD Stage: Phase 2b completed in MASH (IMPACT); Phase 2 in AUD and ALD. What is RECLAIM from Altimmune? RECLAIM: Phase 2 trial of pemvidutide in AUD Stage: Phase 2; enrollment completed. What was Altimmune's revenue last year? $41,000 for the fiscal year ended Dec 31, 2025, as reported to the SEC. Is Altimmune profitable? Altimmune, Inc. reported a net loss of $88.1 million for the fiscal year ended Dec 31, 2025, and used $67.5 million of cash in operations, per its annual report to the SEC. ## Investor discussion: Altimmune Members talk about Altimmune (ALT). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Altimmune, newest first. Each line links the filing it comes from. 1. 2026-04-22 Financings Filed a final prospectus for a securities offering. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1326190/000132619026000031/alt-20260422x424b5.htm) 2. 2026-04-16 Listings Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.03,5.07,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1326190/000132619026000027/alt-20260416x8k.htm) 3. 2026-03-06 Legal Disclosed a shareholder lawsuit, subpoena or other legal matter. SEC Form 10-K. [Source](https://www.sec.gov/Archives/edgar/data/1326190/000132619026000018/alt-20251231x10k.htm) 4. 2026-01-28 Financings Reported a financing. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1326190/000132619026000004/alt-20260128x424b5.htm) 5. 2025-11-06 Legal Disclosed a shareholder lawsuit, subpoena or other legal matter. SEC Form 10-Q. [Source](https://www.sec.gov/Archives/edgar/data/1326190/000132619025000064/alt-20250930x10q.htm) 6. 2025-11-06 Financings Reported a financing. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1326190/000132619025000066/alt-20251106x424b5.htm) 7. 2025-05-13 Legal Disclosed a shareholder lawsuit, subpoena or other legal matter. SEC Form 10-Q. [Source](https://www.sec.gov/Archives/edgar/data/1326190/000132619025000034/alt-20250331x10q.htm) 8. 2025-02-27 Financings Set up an at-the-market program to sell shares over time. SEC Form S-3. [Source](https://www.sec.gov/Archives/edgar/data/1326190/000132619025000019/tmb-20250227xs3.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:ALT on TradingView](https://www.tradingview.com/symbols/NASDAQ-ALT/). ## SEC filings and registration - **SEC name**: Altimmune, Inc. - **CIK**: 1326190 - **Industry (SIC)**: Pharmaceutical Preparations (2834) - **US tickers**: ALT (Nasdaq) - **State or country of incorporation**: DE - **Fiscal year ends**: December 31 - **Filer category**: Non-accelerated filer
Smaller reporting company - **Business address**: 910 CLOPPER ROAD, GAITHERSBURG, MD, 20878 - **Phone**: 2406541450 - **Shares outstanding**: 194,517,701 as of 2026-08-07 (10-Q filed 2026-08-12) - **Former names**: PHARMATHENE, INC; HEALTHCARE ACQUISITION CORP ### Recent filings (8-K and 6-K are the company's own announcements) - [8-K](https://www.sec.gov/Archives/edgar/data/1326190/000132619026000056/alt-20260924x8k.htm) filed 2026-09-29 - [10-Q](https://www.sec.gov/Archives/edgar/data/1326190/000132619026000052/alt-20260630x10q.htm) filed 2026-08-12 - [8-K](https://www.sec.gov/Archives/edgar/data/1326190/000132619026000049/alt-20260812x8k.htm) filed 2026-08-12 - [8-K](https://www.sec.gov/Archives/edgar/data/1326190/000132619026000044/alt-20260728x8k.htm) filed 2026-07-28 - [8-K](https://www.sec.gov/Archives/edgar/data/1326190/000110465926074575/tm2618087d1_8k.htm) filed 2026-06-16 - [10-Q](https://www.sec.gov/Archives/edgar/data/1326190/000132619026000040/alt-20260331x10q.htm) filed 2026-05-13 - [8-K](https://www.sec.gov/Archives/edgar/data/1326190/000132619026000037/alt-20260513x8k.htm) filed 2026-05-13 - [8-K](https://www.sec.gov/Archives/edgar/data/1326190/000110465926048552/tm2612493d2_8k.htm) filed 2026-04-24 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001326190), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details Altimmune, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker ALT, recorded under United States. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Altimmune, Inc. - **Ticker**: ALT - **Listing**: NASDAQ - **Country or territory**: United States - **Business scope**: Biotechnology - **ISIN**: US02155H2004 - **Other listed symbols**: BIVA:ALT1; BMV:ALT1; GETTEX:3G0; LS:A2N5Z6; LSX:A2N5Z6 - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-ALT/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/altimmune/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Altimmune (ALT) news: offering", 2026-10-31, https://aibio.space/companies/altimmune/